Nurix Therapeutics (NRIX) investor relations material

Strategic collaborations and financial structure

• Closed a major partnership with Roche, covering both oncology and immunology, with a $700M upfront payment and up to $1.6B in milestones, plus a 50/50 U.S. profit share and ex-U.S. royalties.

• The deal accelerates clinical development, especially in autoimmune indications like CSU and MS, with immediate plans to file an IND for CSU this year and initiate MS trials next year.

• The partnership provides significant funding flexibility, enabling expansion of the pipeline and self-funding of clinical programs.

Clinical development and pipeline progress

• Lead asset bexobrutideg is in a phase III head-to-head trial against Lilly's Jaypirca in CLL, targeting both BTK-mutant and wild-type populations, with dual primary endpoints (ORR and PFS) and a target enrollment of 600–620 patients.

• A single-arm CLL-201 trial in third-line-plus patients aims for accelerated approval, with prior phase I data showing ORR of 65–80% in late-line and up to 90% in earlier-line patients.

• Non-Hodgkin's lymphoma programs, including Waldenstrom's and MCL, are planned with Roche, focusing on combination approaches in both second-line and frontline settings.

Competitive landscape and differentiation

• Bexobrutideg shows similar efficacy to BeOne's BGB-16673 but may offer a better safety and selectivity profile based on proteomics and molecular analysis.

• The BTK degrader mechanism is believed to overcome resistance mutations and remove BTK's scaffolding function, potentially offering advantages over inhibitors.

• Regular data updates are expected at major conferences, with the next anticipated at ASH.